Find Your Broker
Share Name Share Symbol Market Type Share ISIN Share Description
Verona Pharma LSE:VRP London Ordinary Share GB00BYW2KH80 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -1.50p -1.64% 90.00p 85.00p 95.00p - - - 0 07:41:04
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -25.2 -23.4 - 94.57

Verona Pharma Share Discussion Threads

Showing 12751 to 12775 of 12775 messages
Chat Pages: 511  510  509  508  507  506  505  504  503  502  501  500  Older
Key date approaching for Verona Pharma’s (VRP) shareholders
Rns...encouraging news re CF
New slide set added to the Verona website re Wedbush Investor event; hXXp:// It is interesting since they have put some numbers on the addressable market size in different areas of COPD treatment and their monthly value. If I am reading it correctly they are looking at a total of 3m people in the US at a list price of $970 per month. I don't know what proportion they could win if it gets to market. NDA filing planned for 2021/22. Any thoughts? And has anyone heard the audio today, I am at work so will check it out later.
Seems quite unloved here. I added to my holding today. I suspect a good result in the first quarter 2019 would see a re-rating here. That is only 6 months or so away. They are well funded until then. Perhaps I am missing something but it seems a fair risk/reward ??
AstraZeneca's COPD drug fails to beat out GSK rival hxxps://
I would if my losses were not so big
shakin not stirred
Validation cannot be fast tracked here. If investment not looked at as medium/long term , try something else.
War of attrition on the share price Same old same old for the last 5 Years. Does anybody feel if we get a painter on the BOD it could help us. Or a plumber to stop the share price going down the pan.Is their any other deluded person out their that actually looked at jaks CV and thought he would be the man to take this forward.IMO he has done less than CP And Mr Walker.Wait till the next fund raise this side of Christmas I reckon and then all see the value further diluted to smitherines. Sub 75p imo
shakin not stirred
Interims out for the 6 months to 30th June today. Pretty much as expected in terms of operational & financial information. They've made errors on the dates in some of the financial comparisons with previous periods, so they'll have to issue a correction later.
Singers have just published a new Verona research note which is accessible to those who subscribe to Research Tree Verona Pharma’s RPL554 is a differentiated respiratory programme with broad potential utility, supported by strong clinical data including synergistic effects with standard therapy. Our revised, conservative valuation scenario for Verona Pharma (which forms the basis of our 267p target price) is based solely on US direct sales of RPL554 as a nebulised maintenance treatment of COPD. We stress that this represents a conservative base case valuation to which potential label expansions and additiona .... (subscription required for complete note)
This study could answer a lot of questions: first and foremost which dose should be progressed for the Phase III studies 1.5mg or 6mg? then does it add to a LAMA/LAMA combo and then does it add to a LAMA/LABA/ICS triple therapy. This is gonna be a tough one, but the outcome will hopefully determine which dose to progress and how Verona are going to position RPL554 within the COPD market. I would be slightly surprised (but delighted) if they see a difference in FEV1 at 12 hours vs the LAMA/LABA and I would be surprised (and very delighted) if they see a difference at 12 hours vs the triple therapy, but if they did, we would be off to the races
Verona Pharma (VRP) News Out Just Now
Seems to me they are quite happy to keep going alone until they complete all trials which could be years away and will involve raising more cash. They said they had enough to get part way through phase3. However, I bought a small amount yesterday on the basis that someone like GSK might be keen to partner/takeover at a reasonable price which would realise value here. If not my stake at today's price would hopefully hold its value over the next six months.
Disappointing news this morning for GSK regarding this particular sub group of COPD patients, but I wonder if this might make them look elsewhere for a solution, RPL554 would seem to be an ideal candidate given that as well as being a bronchodilator, it also has anti-inflammatory properties:
Maybe you can be our nomad and drum up some interest. No interest and not surprising with grand incompetence reflected in the share price
shakin not stirred
Bewise looks very encouraging.Trust you have not seen the share price lately. If this is your strong buy shares performance I would hate to see your sell share price performance. Have to laugh at your unrivalled passion for such poor performance.
shakin not stirred
Guys have a look at the vrp website, a new presentation from the Jeffrey healthcare conference, lots of new information regarding timeframes, planned studies etc up to 2021, defo worth a look and very encouraging. A strong buy from me :)
Thanks GersemiSo riskier than our other mutual share Oxb?!People I spoke to in the market (mostly Investors) seriously confident about Verona science/tech
Today's IC - Verona Pharma Verona Pharma (VER) is responsible for the development and potential commercialisation of RPL-554 – a respiratory drug that has the potential to be used in the treatment of asthma, chronic obstructive pulmonary disease (COPD) and cystic fibrosis. RPL-554 differs from most of the products currently available as it combines bronchodilation – opening the airways – and anti-inflammation to treat severely ill patients. Sink: RPL-554 is still only in the second phase of development and therefore has the expensive phase three trial to come. Verona currently only has one drug in the clinical phase of development, meaning the future of the company is entirely dependent on the success of this drug’s clinical trials. The respiratory market is already incredibly crowded, which means commercialisation might be tough even if RPL-554 does gain approval. Revenues aren’t forecast for the foreseeable future, while losses are expected to widen until at least 2020. Swim: The company is aiming to ensure the drug’s dosage and formulation are ideal before progressing to the expensive phase three trial. The high value of respiratory medicines means this is a popular area of specialism for big pharma companies. That could make Verona Pharma a takeover target. Nasdaq listing provides another potential source of capital. Indeed, the group has filed a shelf registration statement with the US’ Security and Exchange Commission – meaning it can issue up to $200m in shares over the next three years. Verona has clinical trials and proven efficacy in three different respiratory illnesses. With just one drug and a great deal of development still to come, Verona remains a high-risk biotech company. The strong evidence that RPL-554 is both safe and effective makes Verona Pharma a potential takeover target for a pharma company with a big respiratory division. Swim. -
Thanks Timbo for attending and reporting on AGM. Did not mention the latest dilution at the AGM. No surprises there. Do not feel current BOD have it in them to get this commercialised if they hàd two lifetimes IMHO.Did they comment on why the share price was so pathetic.
shakin not stirred
Timbo, Firstly many thanks for attending the AGM and reporting back. Do you think there is any credible chance of VRP getting a licensing or partnership deal before phase 3 is done.
>>>Beanol I think I got an honest answer from them on the Ken Newman question (he is no spring chicken), but it is not surprising that the market was unsettled by the news. My largest worry is how they are going to position the drug and what sort of phase III trials will be required to support the positioning The drug undoubtedly works and it would be quite possible to design a phase III program to get it approved either as mono therapy or an add on to existing treatments for maintenance therapy. But how will it administered (as an add on) in a way that is convenient to patients and ensures good compliance and how do VRP ensure that it will find its way on to formularies and reimbursed by healthcare payers?
There is a detailed report on Verona Pharma's recent AGM which can be found in our members area here: hTTps:// To access the report, you'll need to be a full member of ShareSoc, which is a not-for-profit organisation that supports individual shareholders and campaigns for shareholder rights. If you're not already a member you can join here: hTTps:// Once you've joined, you'll receive an invitation to register for our "members network" private social network, from where you'll be able to access the report (and reports on 100s of other meetings). If you're already a member and have any difficulty accessing the report, please do not hesitate to contact us here: hTTps://
Thanks VM Timbo. Very considerate of you. Were you convinced by the replies on Ken Newman's resignation Which has clearly had a drag effect on the SP? It's just the timing, lack of notice and no replacement in place Which jars
Chat Pages: 511  510  509  508  507  506  505  504  503  502  501  500  Older
Your Recent History
Verona Pha..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20181219 07:58:00